AbbVie Puts Up $650M to Join Emerging But Crowded Area of Cancer Drug R&D
AbbVie is now part of a growing group of companies that have turned to China to get a bispecific antibody designed to target PD-1 and VEGF to fight cancer. AbbVie may have more to say about the deal in its presentation this week during the annual J.P. Morgan Healthcare Conference in San Francisco. The post…